DK0458696T3 - Anvendelse af 1-(2-naphtylethyl)-4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyridin til fremstilling af et lægemiddel til behandling af cerebrale og neuronale sygdomme - Google Patents

Anvendelse af 1-(2-naphtylethyl)-4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyridin til fremstilling af et lægemiddel til behandling af cerebrale og neuronale sygdomme

Info

Publication number
DK0458696T3
DK0458696T3 DK91401311.5T DK91401311T DK0458696T3 DK 0458696 T3 DK0458696 T3 DK 0458696T3 DK 91401311 T DK91401311 T DK 91401311T DK 0458696 T3 DK0458696 T3 DK 0458696T3
Authority
DK
Denmark
Prior art keywords
naphthylethyl
tetrahydropyridine
trifluoromethylphenyl
cerebral
medicament
Prior art date
Application number
DK91401311.5T
Other languages
Danish (da)
English (en)
Inventor
Francois Xavier Coude
Jacqueline Fournier
Umberto Guzzi
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of DK0458696T3 publication Critical patent/DK0458696T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK91401311.5T 1990-05-22 1991-05-21 Anvendelse af 1-(2-naphtylethyl)-4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyridin til fremstilling af et lægemiddel til behandling af cerebrale og neuronale sygdomme DK0458696T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9006399A FR2662355B1 (fr) 1990-05-22 1990-05-22 Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Publications (1)

Publication Number Publication Date
DK0458696T3 true DK0458696T3 (da) 1996-05-20

Family

ID=9396855

Family Applications (2)

Application Number Title Priority Date Filing Date
DK91401311.5T DK0458696T3 (da) 1990-05-22 1991-05-21 Anvendelse af 1-(2-naphtylethyl)-4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyridin til fremstilling af et lægemiddel til behandling af cerebrale og neuronale sygdomme
DK94403014T DK0655247T3 (da) 1990-05-22 1991-05-21 Anvendelse af vinkristin til bestemmelse af substanser på neuralt niveau

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK94403014T DK0655247T3 (da) 1990-05-22 1991-05-21 Anvendelse af vinkristin til bestemmelse af substanser på neuralt niveau

Country Status (17)

Country Link
US (3) US5229389A (ja)
EP (2) EP0458696B1 (ja)
JP (2) JP2618115B2 (ja)
KR (1) KR0181330B1 (ja)
AT (2) ATE207747T1 (ja)
BR (1) BR9105015A (ja)
CA (2) CA2042974C (ja)
CY (1) CY2283B1 (ja)
DE (2) DE69132797T2 (ja)
DK (2) DK0458696T3 (ja)
FR (1) FR2662355B1 (ja)
HK (1) HK1001471A1 (ja)
HU (1) HU208922B (ja)
IE (1) IE911707A1 (ja)
IL (3) IL112167A (ja)
TW (1) TW216771B (ja)
ZA (1) ZA913865B (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0192386A (ja) * 1987-10-05 1989-04-11 Hitachi Ltd 密閉循環型吸収式冷凍機及び吸収式冷凍機用吸収液
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
US5618822A (en) * 1990-05-23 1997-04-08 Sanofi N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
US5557209A (en) * 1990-12-20 1996-09-17 Hewlett-Packard Company Identification of pin-open faults by capacitive coupling through the integrated circuit package
FR2690158B1 (fr) * 1992-04-17 1994-07-22 Sanofi Elf Nouveau derive arylpiperidinique, procede pour sa preparation et compositions pharmaceutiques le contenant.
FR2702656B1 (fr) * 1993-03-18 1995-06-16 Sanofi Elf Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs.
US5698565A (en) * 1995-06-09 1997-12-16 Hoffmann-La Roche Inc. Use of phenoxy-pyridine derivatives
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
CA2235747C (en) * 1995-10-26 2006-01-03 Sanofi Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
FR2740343B1 (fr) * 1995-10-26 1999-01-22 Sanofi Sa Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
DE69736976T2 (de) * 1996-03-29 2007-10-18 Trustees Of Boston University, Boston Mit Alzheimer Krankheit verknüpften Verfahren zur Diagnose, zur Herstellung von Medikamenten und zum Screenen von Substanzen sowie aus Beta-Amyloid abgeleiteten Peptiden
US5891465A (en) * 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
FR2757161B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa Diphenylalkyl-tetrahydropyridines
FR2757510B1 (fr) * 1996-12-23 2000-01-07 Sanofi Sa Forme microparticulaire d'un derive de tetrahydropyridine
FR2757512B1 (fr) 1996-12-24 1999-03-12 Sanofi Sa Utilisation de benzoylalkyl-1-1,2,3,6-tetrahydropyridines
CA2279326A1 (fr) * 1997-02-03 1998-08-06 Sanofi-Synthelabo Utilisation du 1-[4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyrid-1yl]-2-(6,7-dimethoxynapht-2-yl)ethane pour la preparation de medicaments destines aux traitements de troubles cerebraux et neuronaux
FR2762514B1 (fr) 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
FR2763847B1 (fr) * 1997-05-28 2003-06-06 Sanofi Sa Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
FR2771007B1 (fr) * 1997-11-14 2000-12-01 Sanofi Sa Association de principes actifs pour le traitement de la demence senile du type alzheimer
CO4980891A1 (es) * 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
DE19751949A1 (de) 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
TWI237035B (en) * 1998-07-24 2005-08-01 Polyplastics Co Polyacetal copolymer
KR101130212B1 (ko) * 2002-03-27 2012-04-13 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 사용법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531707A1 (fr) * 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2639226B1 (fr) * 1988-11-18 1993-11-05 Sanofi Utilisation de trifluoromethylphenyltetrahydropyridines pour la preparation de medicaments destines a combattre les troubles anxio-depressifs
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.

Also Published As

Publication number Publication date
HU911729D0 (en) 1991-12-30
HU208922B (en) 1994-02-28
HUT59824A (en) 1992-07-28
CA2365832A1 (en) 1991-11-23
JP2618115B2 (ja) 1997-06-11
IL112167A (en) 1996-01-31
EP0458696B1 (fr) 1996-01-03
AU636488B2 (en) 1993-04-29
IL98175A0 (en) 1992-06-21
AU7713391A (en) 1991-11-28
CY2283B1 (en) 2003-07-04
IE911707A1 (en) 1991-12-04
EP0655247B1 (fr) 2001-10-31
IE20011078A1 (en) 2002-03-20
TW216771B (ja) 1993-12-01
FR2662355A1 (fr) 1991-11-29
EP0458696A3 (en) 1992-03-18
CA2042974A1 (en) 1991-11-22
ATE207747T1 (de) 2001-11-15
EP0458696A2 (fr) 1991-11-27
DK0655247T3 (da) 2002-02-18
ATE132369T1 (de) 1996-01-15
CA2042974C (en) 2002-09-17
KR910019617A (ko) 1991-12-19
FR2662355B1 (fr) 1994-11-10
ZA913865B (en) 1992-02-26
JPH09132535A (ja) 1997-05-20
IL98175A (en) 1996-01-19
IL112167A0 (en) 1995-03-15
EP0655247A1 (fr) 1995-05-31
DE69132797T2 (de) 2002-05-29
DE69115989D1 (de) 1996-02-15
DE69115989T2 (de) 1996-08-22
KR0181330B1 (ko) 1999-03-20
BR9105015A (pt) 1993-05-25
DE69132797D1 (de) 2001-12-06
HK1001471A1 (en) 1998-06-19
US5468753A (en) 1995-11-21
JPH04226917A (ja) 1992-08-17
US5229389A (en) 1993-07-20
JP2954029B2 (ja) 1999-09-27
US5270320A (en) 1993-12-14
CA2365832C (en) 2007-08-07

Similar Documents

Publication Publication Date Title
DK0458696T3 (da) Anvendelse af 1-(2-naphtylethyl)-4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyridin til fremstilling af et lægemiddel til behandling af cerebrale og neuronale sygdomme
DE288447T1 (de) Ein verfahren und eine zusammensetzung fuer die behandlung neurologischer krankheiten wie migraene, durch beeinflussung der nervenzellen.
DE3889087D1 (de) Integrierter Tintenspritzdruckkopf und Verfahren zu dessen Herstellung.
DE58902445D1 (de) Verfahren zur herstellung von isocyanuratpolyisocyanaten, die nach diesem verfahren erhaltenen verbindungen und ihre verwendung.
DE69425267D1 (de) 3-(3,4-dioxyphenyl)-pyrrolidine als inhibitonen der typ iv - phosphodiesterase zur behandlung von entzündungskrankheiten
DE69111596D1 (de) Verwendung von zwitterionen zur mobilisierung isoelektrisch fokussierter ampholytzonen.
DE69000704D1 (de) Vorrichtung zum lesen der konturen, insbesondere der rahmen von brillen.
DE3777761D1 (de) 2-(2-substituierte benzoyl)-4-(substituierte oxy oder substituierte thio)-1,3-cyclohexandione, verfahren zu deren herstellung, sowie sie enthaltende herbizide zusammensetzung.
DE69635213D1 (de) Verwendung von Olanzapin zur Behandlung von mentalen Erkrankungen verursacht durch zerebrovaskuläre Erkrankungen
DE68925004D1 (de) Verwendung von 2,3,4,5-Tetrahydro-1H-3-Benzazepinen bei der Behandlung von neurologischen Störungen.
DE68900111D1 (de) Diamant-laser und verfahren zu seiner herstellung und zu seinem betrieb.
AT383491B (de) Vorrichtung zum verabreichen von voll- oder sitz- baedern, insbesondere unter verwendung von peloid
ATE174002T1 (de) Verfahren zur reinigung von abfüllanlagen
NO901303L (no) Nye benzotiopyranylaminer.
DE3889043D1 (de) N-(substituiertes Alkyliden)-1,2,3,4-tetrahydro-9-acridinamine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
DE3875543T2 (de) 1-(2-(phenylmethyl)phenyl)-piperazin-verbindungen, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen.
DE3862788D1 (de) Fluessige oxydationsmodifizierte ethylenische statistische copolymere, verfahren zur herstellung und deren verwendung.
ATA271985A (de) Verfahren zur herstellung von n-alkyl/en/-n-/o,o- disubstituierten thiophosphoryl/-n'n'disubstituierten-glycinamiden und diese verbindungen enthaltende akarizide, insektizide und fungizide mittel
DE68926222D1 (de) Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen
DE3863665D1 (de) 2-(benzhydrylsulfonyl) acetamid, verfahren zu dessen herstellung und dessen verwendung in der therapie.
Mahon Early quantitative studies of neuropsychological impairment, 1899–1939.
DE20107360U1 (de) Vorrichtung zur Vorhaltung einer oder mehrerer Compact Disk mit Schutzhülle
IT1231041B (it) Dispositivo per cordare o rivestire per cordatura elementi di cordatura.